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Atrial fibrillation (AF) is the clinically most prevalent rhythm disorder with large impact on quality of life and increased risk for hospitaliza-
tions and mortality in both men and women. In recent years, knowledge regarding epidemiology, risk factors, and patho-physiological
mechanisms of AF has greatly increased. Sex differences have been identified in the prevalence, clinical presentation, associated comorbid-
ities, and therapy outcomes of AF. Although it is known that age-related prevalence of AF is lower in women than in men, women have
worse and often atypical symptoms and worse quality of life as well as a higher risk for adverse events such as stroke and death associated
with AF. In this review, we evaluate what is known about sex differences in AF mechanisms—covering structural, electrophysiological, and
hormonal factors—and underscore areas of knowledge gaps for future studies. Increasing our understanding of mechanisms accounting
for these sex differences in AF is important both for prognostic purposes and the optimization of (targeted, mechanism-based, and sex-
specific) therapeutic approaches.
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Introduction
Atrial fibrillation (AF) is the clinically most prevalent rhythm disorder
with large impact on quality of life and increased risk for hospitaliza-
tions and mortality in both men and women.1,2 In recent years, knowl-
edge regarding epidemiology, risk factors, and patho-physiological
mechanisms of AF has greatly increased.3 Sex differences have
been identified in the prevalence, clinical presentation, associated
comorbidities, and therapy outcomes of AF.4–8 Although it is
known that age-related prevalence of AF is lower in women than
in men,9 women have worse and often atypical symptoms and
worse quality of life as well as a higher risk for adverse events
such as stroke and death associated with AF.10,11 This is
also reflected in the current AF risk algorithms such as the
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CHA2DS2VASc score.
3 Despite the advances in the treatment of
AF, women are more prone to AF recurrences compared to
men.6,11 While the exact mechanism for these sex differences
remains to be elucidated, the importance of structural, electro-
physiological, and hormonal factors have been proposed.6 Data
regarding sex differences in the mechanisms of AF are scarce, and
a better understanding is important both for prognostic purposes
and the optimization of therapeutic approaches.
Based on a thorough electronic literature search conducted using
PubMed, this review evaluates what is known about sex differences
in AF mechanisms and underscores areas of knowledge gaps for fu-
ture studies.
Epidemiology: sex differences in
atrial fibrillation prevalence, age
of onset, clinical presentation, and
co-morbidities
Atrial fibrillation is more common in men (0.06%) than in women
(0.04%).12 In observational studies in Western countries, women
have 30–50% lower age-adjusted incidence and prevalence of AF, in-
dicating that the substrate for AF develops less readily in women. In
East/Asian countries, overall AF prevalence is lower than in Western
countries for which reports regarding sex distribution have been less
consistent varying from equal to lower prevalence in women than in
men.13 In general, AF incidence increases with age for both sexes.
Given the higher life expectancy of women, the absolute numbers
and lifetime risk (23%) for AF are similar in both sexes.14 The pre-
vailing mechanisms predisposing to AF, however, differ between men
and women (Table 1), as highlighted in the following chapters.
Women are more likely to present with persistent AF and atypical
symptoms (weakness and fatigue) and to report a worse quality of
life than men.5 Although asymptomatic AF is less common among
women,15 atypical symptoms may delay diagnosis and therapy and
may contribute to the worse outcomes seen in women.16
Sex differences in atrial fibrillation
subtypes
Idiopathic atrial fibrillation and genetic atrial fibrillation
Genetic predisposition has been attributed to individuals with familial
aggregation of early-onset idiopathic AF, but data on sex-specific dif-
ferences in idiopathic AF have been controversial.17 Mothers of
patients with AF or atrial flutter and women with >_2 affected siblings
have higher AF risk than their male counterparts.18 Similarly, a small
study observed that more women had familial idiopathic AF.19 This is
in contrast to a large registry, which showed that men with a 1st de-
gree relative with idiopathic AF have 37% higher AF risk than
women.20 The genetic basis of these differences is not known, but
X-linked variants of the protective KCNE5 gene and a deletion in the
EMD gene have been proposed as contributing factors.21,22
Exercise-associated atrial fibrillation and autonomic
atrial fibrillation
Pronounced sex differences exist in the connection between exer-
cise and AF: moderate exercise reduces the risk of AF in women
(8.6%), and intense exercise is able to reduce AF risk in women
even more by 30%. In male patients, moderate exercise also reduces
AF risk. Strong exercise, however, increases the risk for AF in men,
pointing towards a U-shape relation in men.23–27 Excessive endur-
ance sports (e.g. more than 1500 h of sports/year) increases the risk
of AF three times in men. These patients also have higher recurrence
rates after pulmonary vein isolation (PVI).28–30
....................................................................................................................................................................................................................
Table 1 Sex differences in prevailing mechanisms/diseases predisposing to atrial fibrillation
Men Women
Prevailing risk factors/diseases
predisposing to AF
Coronary heart disease and cardiovascular risk factors Heart failure, particularly diastolic heart failure (HFpEF)
Excessive sports (vagal AF) Hypertension and left ventricular hypertrophy
Valvular heart disease
High BMI/metabolic disease (increased epicardial fat) High BMI/metabolic disease/epicardial fat
Potential pro-arrhythmic mechanisms increasing
AF prevalence in men
Potential anti-arrhythmic mechanisms reducing
AF prevalence in premenopausal women
Hormonal effects impacting
on AF prevalence
Detrimental testosterone effects on atherosclerosis/
CAD
Beneficial oestrogen-effects on cardiovascular risk
factors
Pro-arrhythmic testosterone effects on atrial electrical
features (shorter APD facilitating re-entry)
Anti-arrhythmic oestrogen-effects on atrial electrical
features (longer atrial APD)
More pronounced fibrotic remodelling in male animals
(testosterone-effect?)
Beneficial oestrogen-effects on structural remodelling
(attenuation of fibrosis)
Beneficial oestrogen-effects on diastolic function
Reduction of epicardial fat (by oestrogen? indirect evi-
dence: more epicardial fat in post-menopausal
women)
AF, atrial fibrillation; APD, action potential duration; BMI, body mass index; CAD, coronary artery disease; HFpEF, heart failure with preserved ejection fraction.
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Male athletes show more marked concentric ventricular and atrial
remodelling with altered diastolic function, which associates with a
higher blood pressure during exercise as well as a higher sympathetic
tone compared to female athletes.31 This atrial remodelling might be
a reason for the higher rate of AF in sportsmen.31 In addition, studies
in rat models revealed that long-term endurance exercise causes a
combination of structural remodelling and (central and end-organ)
vagal enhancement,32 which may further promote re-entry by caus-
ing spatially heterogeneous shortening of atrial refractoriness.33
Indeed, despite the observation of an overall higher sympathetic tone
during exercise,31 in (male) athletes, paroxysmal AF occurs three
times more often in situations of high vagal tone (such as rest, sleep,
or postprandial) than in non-athletes.34 In line with these observa-
tions, a low heart rate has generally been associated with an in-
creased risk for AF.35
While in young male athletes, these vagal triggers predominate; in
post-menopausal women an increased predominant sympathetic
tone is observed.36,37 This increased sympathetic/parasympathetic
balance has generally been associated with a high risk of AF35 and is
particularly often associated with AF in organic heart disease and
post-cardiac surgeries.38
Co-morbidity-associated atrial fibrillation
Women often develop AF at an older age than men.39 In the
Framingham Heart Study, for example, 74% of women with AF were
aged >_70 years compared to only 58% of men, strongly suggesting
that more comorbidity may be present and possibly causative in
women with AF1 (Table 1).
All classic cardiovascular risk factors, except for diabetes, are pre-
dictive of AF in both sexes. High body mass index (BMI) has been
shown to be the strongest predictor for AF with a higher hazard ratio
in men than in women. Moderate alcohol intake increases the risk for
AF only in men, while high alcohol intake is associated with a height-
ened AF risk in both sexes.40,41 No sex-specific differences have been
consistently demonstrated for other risk factors such as hyperthy-
roidism.25,39,41–43
Several comorbidities, however, are differently associated with AF
in men and women: women with heart failure have a 14-fold risk and
men a 8.5-fold risk of developing AF.44 In addition, AF is an indepen-
dent risk factor for new onset heart failure with preserved ejection
fraction (HFpEF) in women but not in men.45 Although over the past
50 years the prevalence of valvular heart disease has generally de-
creased in women with AF in high income countries, there is still a
higher prevalence of valvular heart disease and hypertension and
lower prevalence of coronary heart disease in women than in men
with AF.1,8,46
Sex hormone effects on atrial fibrillation
Atrial fibrillation in menopausal and post-menopausal
women
The incidence of AF in premenopausal women is low but the inci-
dence increases after menopause particularly at ages over 50 years,
suggesting a beneficial effect of oestrogen and/or a harmful effect of
post-menopausal hormonal changes—such as the pronounced de-
crease in oestrogen—with regards to the development of AF.13
With the decrease of oestrogen levels during menopause, blood
pressure, low-density lipoprotein cholesterol, metabolic syndrome,
and BMI increase. All these effects are well-established risk factors
for developing AF47 and their increase after menopause may explain
the partial catch up in the incidence of AF in post-menopausal
women (Table 1).
In line with these observations, there is evidence for a higher inci-
dence of AF in patients undergoing anti-oestrogen treatment and for
a lower risk of AF with (oestrogen-based) hormonal replacement
therapy, albeit published data are conflicting.48–50 While oestradiol
was shown to reduce the risk for AF,51 conjugated oestrogens alone
have been reported to increase AF risk (two-fold compared to oes-
tradiol)51,52 and combined oestrogen-progesterone based hormonal
replacement therapy had either no effect52 or decreased AF inci-
dence,49 suggesting a complex interaction and an impact of the hor-
monal preparation and its oestrogen-receptor specificity.
Atrial fibrillation during pregnancy and postpartum
Observational studies suggest that pregnancy may exacerbate supra-
ventricular tachycardias in general.53 Prevalence of AF in pregnant
women, however, is very low (0.05%)54 and is generally limited to
patients with structural heart disease, in which AF incidence is a little
higher (1.3%).55 Nevertheless, several electrical and electro-
mechanical changes have been observed during pregnancy such as an
increase in P wave duration and dispersion and in atrial electro-
mechanical coupling interval measured by tissue doppler56 that are
well-known markers for increased AF incidence in normal hearts. As
these observations were made in patients with pre-eclampsia, how-
ever, it is unclear whether these are alterations normally occurring
during pregnancy or being simply associated with the vascular/atrial
susceptibility of an abnormal pregnancy. Atrial fibrillation during the
peripartum period may occur mainly due to drug therapy such as ter-
butaline during tocolysis57,58 and also as an expression of peripartum
cardiomyopathy.59
Atrial fibrillation and testosterone
The epidemiological data on the link between AF and testosterone
are conflicting. Data from the Framingham study show an association
between AF incidence and reduced total testosterone levels in men
aged 55 years and above, with the strongest association seen in men
>_80 years of age, with a 3.5-fold increase in AF risk for every standard
deviation reduction in testosterone levels.60 Similarly, a smaller
cross-sectional study demonstrated a similar association between re-
duced testosterone levels and lone AF.61 In contrast, the Multi-Ethnic
Study of Atherosclerosis study showed that higher levels of endoge-
nous bioavailable testosterone seemed to contribute to AF develop-
ment.62 The differences in findings may in part be due to
methodological differences in measuring testosterone (total vs. bio-
available testosterone) but may also relate to competing mechanisms
of direct and indirect testosterone effects.
The data on the effects of testosterone replacement are equally
conflicting. In a recent study on >76 000 individuals, normalization of
testosterone levels with replacement therapy was associated with a
decreased incidence of AF.63 However, preclinical studies have
shown the opposite effect, with testosterone replacement increasing
arrhythmogenesis in pulmonary veins (PVs) and the left atrium, prob-
ably by enhancing adrenergic activity.64
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Mechanisms underlying sex
differences in atrial fibrillation
Sex differences in electrophysiological
properties of atria
Sex differences in electrophysiology and calcium handling
Experimental models show sex differences in the electrophysiology
of the left atrium. In male mice, PVs have a higher spontaneous beat-
ing rate, increased burst firing and more delayed afterdepolarizations
(57% vs. 16%).65 Additionally, male mice have slower sino-atrial im-
pulse-generation activity. Thus, spontaneously higher PV beating
rates can compete with sino-atrial activity leading to arrhythmias. Sex
differences in arrhythmogenesis can also be explained by differences
in calcium and sodium channel regulation.66 Mouse studies have
shown that late sodium current, calcium transients, and sarcoplasmic
reticulum calcium contents of the posterior wall of the left atrium
were greater in male cardiomyocytes than in females, which may con-
tribute to increased ectopic activity.66 Interestingly, no differences
were found in the right atrium.
In contrast, a clinical study in women undergoing AV nodal reentry
tachycardia ablation showed shorter atrial effective refractory period
(AERP) in women rather than longer.67 In a small cohort of patients
that underwent AF ablation,68 these sex differences in AERP were
not confirmed, likely due to some electrical (and structural) remodel-
ling present in these patients with paroxysmal AF. This small study
suggested that the prevalence of non-PVI triggers was significantly
more frequent in women than in men (16% vs. 8.4%).
Sex hormone effects on electrophysiology and calcium
handling
Cardiac myocytes express oestrogen and androgene receptors,
strongly suggesting that sex hormones may directly affect ion chan-
nels and their expression.69,70
Most research has focused on sex hormone effects on ion chan-
nels/currents expressed in atria and ventricles. Testosterone
increases repolarizing IKr, IK1, and IKs,
71,72 and acutely reduces ICa,L.
73
Oestrogen exerts complex effects on IKr
74: it blocks IKr directly
75 but
may also increase IKr by promoting HERG trafficking.
76 In addition,
oestrogen reduces IKs by reducing its beta-subunit KCNE1,
77 reduces
Ito,
78 and increases ICa,L.
79 These alterations of ion currents result in a
net oestrogen-induced prolongation of action potential duration
(APD) and QT interval and a net testosterone-induced shortening of
APD/QT (Figure 1).80 The shortened APD in male atria may be pro-
arrhythmic by facilitating re-entry, while the longer APD in female
atria may exert anti-arrhythmic effects relating to AF (contrasting
with its pro-arrhythmic effects in the ventricles). As most studies on
hormone effects on ion currents were performed in ventricular car-
diomyocytes, the transferability to the atrial electrical phenotype
needs confirmation.
Only few data are available on sex hormone effects on ‘atrial’ ion
channels/currents and most were derived from non-cardiac tissue
also expressing these channels. During pregnancy (with high oestro-
gen levels), If current densities and automaticity are increased in
mice.81 Oestrogen upregulates Ca2þ-activated small conductance
potassium channels (SK3) in colonic smooth muscle cells82 and
downregulates two-pore domain Kþ channels (TASK-1) in neural
cells (Figure 1).83 A likewise oestrogen-induced reduction of TASK-1
in the atria would prolong the atrial APD and exert pro-arrhythmic
effects, as demonstrated in patients with lone AF harbouring loss-of-
function mutations in KCNK3/TASK-1.84 As SK expression has been
demonstrated to be particularly high in the PVs (as compared to the
rest of the atria),85 oestrogen-induced changes in SK expression
might modulate triggered activity from the PVs. Whether similar
oestrogen-effects are indeed observed in the atria, however, needs
to be assessed.
Sex hormone effects on calcium handling properties can also con-
tribute to atrial arrhythmogenesis: oestrogen increases the propen-
sity for triggered activity by increasing ICa,L,
79 NCX activity,86 and
RyR2 leakiness.87 Testosterone in contrast reduces triggered activity
by increasing SERCA activity,79,88 and decreasing ICa,L (Figure 1).
73
In line with these findings, testosterone deficiency facilitates atrial
arrhythmia by reducing binding of FKBP12.6 to RyR2 resulting in in-
creased calcium leakage.89
Sex differences in electrical remodelling
There is little direct evidence on whether sex differences in atrial
electrical remodelling play a role in sex differences in AF risk.
Biochemical and histological analysis of atrial tissue obtained during
cardiac surgery showed that remodelling-induced changes of connex-
ins and collagen in AF are broadly similar between men and women,
though women exhibited somewhat stronger AF-induced increase in
Cx40.90 Indirect evidence indicating that sex may be an important de-
terminant of the degree of electrical remodelling in the left atrium
comes from a study on heart failure patients. Analysis of mRNA ex-
pression of genes encoding for ion channel subunits important in car-
diac conduction and arrhythmogenesis in left atria of explanted
human hearts showed differential remodelling between sexes, with
lower expression levels in transcripts encoding for K(v)4.3, KChIP2,
K(v)1.5, and K(ir)3.1 in the failing female left atrium as compared with
the male left atrium.91 Differential electrical remodelling between
sexes was also seen in a study in rabbits on left ventricular (LV) hy-
pertrophy with less pronounced APD prolongation in left ventricles
in females than in males leading to longer APD in males than
females—thus reversing the sex differences observed at baseline.92
Whether similar sex differences in remodelling also occur in the atria
remains to be investigated.
Sex differences in structure and function
of atria
Sex differences in atrial anatomy, structure, and function
Morphological, structural, and functional sex differences in the atria
have been described in association with AF. Healthy women have
smaller maximal left atrial volumes (89 ± 21 mL vs. 103 ± 30 mL),
smaller left atrial anteroposterior diameter, and lower left atrial
stroke volumes (48 ± 15 mL vs. 58± 23 mL).93,94 In addition, magnetic
resonance imaging (MRI) analyses revealed sex differences in atrial
mechanical function in healthy subjects, e.g. in atrial conduit and
booster pump function.95,96 In contrast to the observations in healthy
subjects, women referred for AF ablation usually have larger atria
than men,97 which may be partly due to the facts that these women
were older, had a longer AF history, more hypertension, and more
valve disease than the men in the study.
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Tissue fibrosis plays a major role in the development of AF and its
progression to a persistent/permanent status. Sex differences regard-
ing the degree of fibrosis in the different clinical variants of AF were
demonstrated by histopathological studies and with MRI.98 It is not
clear, whether these sex differences in the extent of fibrosis with
more pronounced fibrosis in women are mainly due to inherent dif-
ferential expression of fibrosis-related genes and proteins or due to
the age of men and women with AF (younger age in men with AF).90
A study looking at PV sleeves from patients with and without long-
standing persistent AF demonstrated increased fibrosis in females
with AF.90 These sex differences in fibrosis remodelling in longstanding
persistent AF were mainly due to the inherent differential expression
of fibrosis-related genes and proteins, with those related to the
TGFb/Smad3 pathway being up-regulated in females, suggesting sex-
specific aggravation of fibrosis remodelling. There is also evidence to
suggest that this more extensive left atrial structural remodelling leads
to greater deterioration in left atrial appendage function in women
with high calculated risk of stroke in AF compared with men.99
Sex hormone effects on atrial mechanical function
Data on sex hormone effects on atrial function were obtained in animal
studies. In rats, androgens produce acute vasodilation, increase con-
tractility, and increase the sino-atrial recovery time by depressing spon-
taneous depolarization involved in atrial pacemaking.100 Androgens
cause a larger response to inotropes in male atria via a post-synaptic in-
crease in intracellular cAMP and independently of beta1-adrenocep-
tors.101 In female mice though, oestrogens are those that drive the
sensitivity to catecholamine by down-regulating the beta1-receptors,
depending on the oestrous cycle.102 In female sheep, in contrast, oes-
trogen causes LV enlargement and increased stroke volume.103
Sex hormones also modify the response to volume overload and
the secretion of atrial natriuretic peptide (ANP) as demonstrated in
A
B
Oestradiol
Figure 1 (A) Schematic figure indicating sex hormone effects on cardiac ion channels/currents and calcium handling proteins in cardiomyocytes.
Effects on ion channels that have thus far only been demonstrated in non-cardiac tissues are indicated in the left corner separated by green dotted lines.
Oestrogen-induced changes are colour-coded in red, testosterone-induced changes in turquoise. (B) Illustration of resulting effects on cardiac repolari-
zation and arrhythmogenic mechanisms. - - -, reduction;þþþ, increase; ", increase/prolongation, #, decrease/abbreviation. AERP, atrial effective refrac-
tory period; APD, action potential duration; DHT, testosterone; EAD, early afterdepolarization; eNOS, endothelial nitric oxide synthase; EST,
oestrogen; IL, interleukin; PAI 1, plasminogen-activator inhibitor 1; SR, sarcoplasmic reticulum; TdP, Torsade-de-Pointes; HERG/IKr, alpha-subunit to
repolarizing delayed rectifier potassium current IKr; KvLQT1/IKs, alpha-subunit to repolarizing slow delayed rectifier potassium current IKs, Kir2.1/IK1;
SCN5A/INa, alpha-subunit to depolarizing sodium current INa; Cav2.1/ICa,L, alpha-subunit to L-type calcium current ICa,L; SK3, small-conductance cal-
cium-activated potassium channel; TASK-1, two-pore domain potassium channel; TNF, tumor necrosis factor; VGEF, vascular endothelial growth factor.
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studies in rats. Oestrogen increases the basal secretion but does not
influence the stretch-induced ANP secretion. In contrast, although
testosterone does not affect basal secretion, it completely abolishes
the stretch-induced increase in ANP secretion.104
Sex differences in structural remodelling of the heart
the atria
Animal data suggest sex-specific differences in pathological remodel-
ling. In mouse models of myocarditis as well as in models of
isoproterenol-induced heart failure, fibrotic responses are generally
more prominent in male mice, showing higher numbers of TLR4þ
CD11bþ monocytes, neutrophils, mast cells, and dendritic cells, and
increased Th1 helper cell responses compared to females.105 In con-
trast, protective Th2 responses, increased B cells, more inhibitory
Tim-3þ CD4þ T cells, and more T regulatory cells dominate the
picture in female animals.105,106 Consistent with these findings, intra-
cardiac macrophages from male mice preferentially expressed iNOS,
IL-12, TNF-a, and CD16/32, markers associated with M1 activa-
tion,107,108 while heart-infiltrating macrophages in females showed a
M2 activation pattern including arginase 1, IL-10, and M/-MR
expression.
Fibrosis is an event that affects the atria as well as the ventricles,
and several lines of evidence suggest that oestrogens indeed play an
important role in attenuating this process of adverse remodelling.
Thus, it is not surprising that expression of fibrosis-related genes,
mainly those related to the TGFb/Smad3 pathway, is up-regulated in
post-menopausal women with AF (Figure 2).100 Nevertheless, the ex-
act mechanisms through which sex modulates structural atrial
remodelling still remain to be identified.109
Sex differences in cardiac autonomic
modulation and neuro-humoral
responses
Sex differences in cardiac autonomic activity
The autonomic nervous system (ANS) including the sympathetic and
parasympathetic system and the intrinsic neuronal network—and its
alterations—plays an important role in the pathogenesis of AF.110–112
Both parts of the ANS are involved in the initiation and maintenance
of AF. The role of the parasympathetic system in AF is mainly attrib-
uted to the shortening in APD and increased dispersion of refractori-
ness in the atrial myocardium facilitating initiation and maintenance of
AF.33 Vagal activation exerts these effects mostly via acetylcholine ac-
tivated Kþ channels.113 Sympathetic stimulation can also promote AF
by increasing Ca2þ release; thereby causing afterdepolarization for-
mation as a trigger for AF (Figure 3).
When compared to men of the same age, women seem to have
more dominant vagal tone indexed by measures of heart rate variabil-
ity,114,115 although this sex difference disappears with aging (and con-
secutive changes in hormones).116
Sex hormones influence the autonomic tone. As the adrenergic
tone influences conduction properties and refractoriness of cardiac
tissue,117 these hormone effects on the autonomic system may con-
tribute to sex differences in the electrophysiological properties of
the heart.118 Low levels of oestrogen and elevated levels of proges-
terone increase catecholamine levels, and there is higher sympathetic
activity in the luteal phase of the menstrual cycle (which is character-
ized by low oestrogen and high progesterone levels).119,120 Similarly,
in post-menopausal women an increased predominant sympathetic
tone is associated with reduced oestrogen levels.36,37
Oestrogen
Figure 2 Schematic figure indicating effects of menopause-associated reduction in oestrogen on epicardial fat and related (pro-inflammatory) sig-
nalling pathways and fibrotic remodelling mechanisms. ", increase/activation, #, decrease; MCP-1, monocyte chemoattractant protein-1; ROS, reac-
tive oxygen species.
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Sex differences in neuro-humoral responses
A complex nervous system controls the cardiovascular system and
affects the arterial pressure, heart rate, and cardiac contractility. This
neural control of the heart and vascular system is related to the
sympatho-vagal balance and is regulated by vascular feedback. The re-
nin–angiotensin system and natriuretic peptides, for example, con-
tribute to the regulation of the cardiovascular system, partially acting
as cardiac hormones.
Physiologically, women have a lower responsiveness of the mecha-
nisms regulating arterial pressure.121 In addition, women have higher
values of natriuretic peptides.122
Studies evaluating sex differences in neuro-humoral control of the
cardiovascular system in pathological conditions are scarce. Electrical
and structural remodelling in AF does not seem to be mediated by
changes in autonomic tone.123 But neuro-humoral activation could
be involved in differences of atrial fibrosis development via the renin–
angiotensin–aldosterone system thus potentially contributing to dif-
ferences in AF development.124
Sex differences in impact of
co-morbidities
Sex differences in heart failure with preserved ejection
fraction and endothelial dysfunction
Heart failure with preserved ejection fraction and diastolic dysfunc-
tion are associated with a high prevalence of AF.125 This has impor-
tant implications, as AF is associated with poorer outcome in patients
with HFpEF in general and women in particular.126 Both, similar risk
factors for AF and HFpEF and the haemodynamic consequences of
diastolic dysfunction at the atrial level likely play a causative role.125
Importantly, it has been shown in different populations that women
have an increased age-related risk of developing diastolic dysfunction
or HFpEF as compared to men.126–128 At the atrial level, this is
reflected by a greater atrial functional decay with age in women, as
measured by longitudinal strain rate.129 The age-related higher risk of
diastolic dysfunction in women suggests a relation with oestrogen de-
ficiency after menopause. Indeed, animal studies indicate a number of
pathways, by which oestrogen deficiency can modulate diastolic dys-
function, including enhanced cardiac remodelling, LV hypertrophy
and increased arterial stiffness.39,130,131 In a large human population
study, arterial stiffness leading to diastolic dysfunction has also been
shown to be greater in women.132 Despite the fact that hormone re-
placement therapy does not result in survival benefit in large studies,
it does lead to improvement of diastolic function in post-menopausal
women,133,134 which may contribute to the reduced AF incidence
observed with oestrogen replacement therapy. These studies con-
firm the role of oestrogen deficiency in the aetiology of diastolic dys-
function and HFpEF (Table 1).
Women also have a higher rate of microvascular disease com-
pared to men. Most of these patients with microvascular disease are
in the peri-menopausal age range (45–60 years), suggesting a similar
relation with oestrogen deficiency. Patients with microvascular dis-
ease are known to have a high prevalence of AF.135 Interestingly,
treatment with ranolazine, which exerts anti-anginal effects but also
impacts on cardiac electrophysiology, can reduce the burden of AF in
these patients.135
Sex differences in pro-inflammatory signalling, role of
epicardial fat
Several lines of evidence suggest an association between epicardial
fat and AF.136 Epicardial fat correlates with a higher prevalence of AF,
a progression to atrial fibrosis and permanent AF and even a higher
recurrence rate after ablation.137,138 Moreover, the extent of
Figure 3 Schematic figure indicating electrophysiological effects of vagal and sympathetic activity on action potential duration and triggered activity
and their changes by endurance sport and menopause. - - -, reduction;þþþ, increase; ", increase/prolongation, #, decrease/abbreviation; APD, ac-
tion potential duration; AERP, atrial effective refractory period.
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epicardial atrial tissue is associated with lower bipolar voltage and
electrogram fractionation in electro-anatomic mapping during sinus
rhythm.139 It has been demonstrated that the secretome from human
epicardial adipose tissue induces myocardial fibrosis through the se-
cretion of adipo-fibrokines.140,141 Tissue fibrosis reflects a chronic in-
flammatory process. In fact, accumulation of fat tissue triggers a
chronic low-grade activation of the innate immune system. Epicardial
adipocytes are able to release pro-inflammatory adipokines and acti-
vate the chemotactic monocyte chemoattractant protein-1 (MCP-1)/
C-C chemokine receptor 2 (CCR2) pathways to promote inflamma-
tory macrophage accumulation (Figure 2). The crosstalk between adi-
pocytes and inflammatory cells depends on the release of cytokines
(IL-1, IL-6, and TNF-a) by fat tissue macrophages.140 Other pro-
inflammatory adipokines like leptin and resistin are also associated
with incident AF in women.142 Menopausal hormonal changes are re-
lated to an increase in epicardial fat and metabolic syndrome inci-
dence,143 risk factors for AF development and prognosis.144 Taken
together, the association between increased epicardial fat and hor-
monal changes in post-menopausal women on one hand, as well as
the causal link between epicardial fat, chronic inflammation, atrial fi-
brosis, and AF burden on the other hand, all point to a protective
role of female sex hormones against AF development and progres-
sion (Figure 2).
Clinical implications for future
therapies and research
How can we use the known mechanistic
findings for future sex-specific diagnostic
and therapeutic strategies?
Based on the mechanistic findings discussed above, several sex-
specific therapeutic strategies might complement our current ‘gen-
eral’ treatment approaches. In the following, we will highlight a few.
As many repolarizing ion currents are lower and APD prolonged in
female atria and ventricles (Sex hormone effects on electrophysiol-
ogy and calcium handling section), Class III drugs further prolonging
APD might be anti-arrhythmic at the atrial level at lower dosages
compared to men but carry an inherent more pronounced risk of
ventricular pro-arrhythmia in women even when used at low dose.
Non-pulmonary triggered activity is more often found in women
(Sex differences in electrophysiology and calcium handling section),
suggesting that the success of AF ablation in women might be in-
creased if other triggers apart from PV triggers are additionally tack-
led. As women demonstrate more pronounced AF-associated
fibrotic remodelling due to an up-regulation of the TGFb/Smad3
pathway (Sex differences in atrial anatomy, structure, and function
section/Sex differences in structural remodelling of the heart the atria
section), antifibrotic drugs (such as angiotensin receptor blockers or
spironolactone) might be beneficial in women—particularly if specifi-
cally targeting this pathway. Similarly, the fact that epicardial adipo-
cyte infiltration and consecutive pro-inflammatory signalling increase
in post-menopausal women (Sex differences in pro-inflammatory sig-
nalling, role of epicardial fat section) indicates that complementing
classical anti-arrhythmic therapies with anti-inflammatory treatment
approaches might be beneficial in older women. Generally,
co-morbidities such as microvascular diseases or diastolic dysfunction
are more often encountered in women with AF than in men (Co-
morbidity-associated atrial fibrillation section/Sex differences in heart
failure with preserved ejection fraction and endothelial dysfunction
section), suggesting that drugs affecting these co-morbidities might be
particularly efficient in women, when added to classical anti-
arrhythmic therapies. As oestrogen has a beneficial/protective effect
and the lack of oestrogen after menopause a harmful effect on several
factors predisposing to AF (Table 1), oestrogen-based hormone re-
placement therapy in post-menopausal women may reduce AF inci-
dence by reducing HFpEF and HFpEF-related AF, by impacting on
electrical features and on structural remodelling and might therefore
reduce AF burden in this population. However, the exact hormonal
preparation might be important for anti-arrhythmic/protective effects
as a reduced AF incidence has only been observed with oestradiol
and oestrogenþprogesterone but not with conjugated (equine)
oestrogens.52
What are current gaps of knowledge that
we need to close to reach this aim?
As highlighted above, epidemiological and experimental evidence
suggests that sex-specific differences in physiological, electrical, and
structural characteristics of the atria and, particularly, in pathological
remodelling of cardiac tissue in AF exist. It is still unclear, however, (i)
to what extent sex differences are due to direct effects of female sex
hormones, (ii) to what extent they are mediated by male sex hor-
mone effects, or (iii) whether they mainly reflect the lack of female
sex hormones in a post-menopausal population of women causa-
tively linked to changes in co-morbidities thereby indirectly impacting
on AF risk. Epidemiologic data indeed point to a direct protective
role for oestrogens in this context, but mechanistic concepts are still
based on observational reports and insights from animal studies.
Here, more detailed mechanistic studies—ideally directly performed
in human atrial tissue and cells—are warranted to increase our
patho-physiological understanding and to reveal important pathways.
This is mandatory to develop targeted, mechanism-based, pathway-
and sex-specific therapies—either based on drugs, or on a combina-
tion of drugs with more specific ablation strategies.
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